BioSpace News Archive

New AmSky™ blister system, the latest in Amcor’s recent innovation breakthroughs, has the potential to transform the sustainability of healthcare packaging

New Peripheral Advantage® Program Delivers Skills and Assets That Empower Nurses to Improve Patient Outcomes with First-Stick Success

Covetrus (NASDAQ:CVET), a global leader in animal-health technology and services, announced today that it will release first quarter 2021 results after the market closes on Thursday, May 6, 2021.

Focus on non-hospitalized patients based on prior data supporting Leukine’s role in improving lung function and enhanced COVID-19 specific immune response

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing and manufacturing niche generic products, announced that Marc Bregman, CPA, has been appointed as Chief Financial Officer, effective May 17, 2021.

Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of a new COVID-19 mouse model.

SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today announced that new data from a study summarizing the predictive value of the PARIS® Test across solid tumor cancers will be presented during a poster session (abstract number 2602) at the American Society of Clinical Oncology annual meeting,

The international rare disease patient advocacy organization, Global Genes, is pleased to announce the 6th Annual RARE Drug Development Symposium in partnership with the Orphan Disease Center of the University of Pennsylvania.

Illumina, Inc. announced that it has filed an action in the General Court of the European Union asking for annulment of the European Commission’s decision asserting jurisdiction to review Illumina’s acquisition of GRAIL.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced it has entered into a securities purchase agreement with North American institutional investors for the purchase and sale of 7,647,000 shares of common stock for gross proceeds of approximately $10.8 million in a registered direct offering.